UMRX Unum Therapeutics

Cogent Biosciences Announces Participation at Upcoming Investor Conferences

Cogent Biosciences Announces Participation at Upcoming Investor Conferences

WALTHAM, Mass. and BOULDER, Colo., Nov. 09, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that management will participate in the following upcoming investor conferences:

  • Jefferies London Healthcare Conference - Wednesday, November 16, 2022 at 11:30 a.m. GMT (6:30 a.m. ET)

  • Piper Sandler 34th Annual Healthcare Conference - Wednesday, November 30, 2022 at 11:00 a.m. ET

A live webcast of each event can be accessed on the Investors & Media page of Cogent’s website at /events. A replay of the webcasts will be available approximately two hours after the completion of the events and will be archived for up to 30 days following each presentation.

About Cogent Biosciences, Inc.

Cogent Biosciences is a biotechnology company focused on developing precision therapies for genetically defined diseases. The most advanced clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling. In addition to bezuclastinib, the Cogent Research Team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting FGFR2 and ErbB2. Cogent Biosciences is based in Waltham, MA and Boulder, CO.

Contact:

Christi Waarich

Senior Director, Investor Relations



617-830-1653



EN
09/11/2022

Underlying

UMRXUnum Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Unum Therapeutics

 PRESS RELEASE
Free
UMRX Unum Therapeuti...

Cogent Biosciences Announces Positive Top-line Results of APEX Trial o...

Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) -- Bezuclastinib demonstrated rapid and deep clinical benefit in AdvSM patients resulting in an objective response rate (CR+CRh+PR+CI) of 57% per mIWG criteria and 80% per PPR criteria -- -- Bezuclastinib demonstrated a powerful effect on mast cell burden with 89% of patients achieving ≥50% reduction in bone marrow mast cells or clearance of aggregates – -- Bezuclastinib was very well tolerated with only 14.8% of patients requiring dose reduction an...

December 8, 2025 1 EN
 PRESS RELEASE
Free
UMRX Unum Therapeuti...

Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Pa...

Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH) -- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline -- -- Bezuclastinib demonstrates that reducing objective measures of disease, including serum tryptase, correlates with improvement in symptom severity; the first time this has been shown in NonAdvSM patients -- -...

December 6, 2025 1 EN
 PRESS RELEASE
Free
UMRX Unum Therapeuti...

Cogent Biosciences Announces Participation in the Jefferies Global Hea...

Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference WALTHAM, Mass. and BOULDER, Colo., Nov. 14, 2025 (GLOBE NEWSWIRE) --  (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 11:30 a.m. GMT (6:30 a.m. ET). A live webcast will be available on the Investors & Media page of Cogent’s website at . A replay of the webcast will be available approximately two hours after the...

November 14, 2025 1 EN
 PRESS RELEASE
Free
UMRX Unum Therapeuti...

Cogent Biosciences Announces Pricing of Concurrent Public Offerings of...

Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031 WALTHAM, Mass. and BOULDER, Colo., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of its previously announced underwritten public offering of 9,677,420 shares of its common stock at a public offering price of $31.00 per share (such offering, the “Equity Offering”) and its underwritten public offeri...

November 12, 2025 1 EN
 PRESS RELEASE
Free
UMRX Unum Therapeuti...

Cogent Biosciences Announces Proposed Concurrent Public Offerings of C...

Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock WALTHAM, Mass. and BOULDER, Colo., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that it has commenced underwritten public offerings of $200 million aggregate principal amount of its convertible senior notes due 2031 (the “Convertible Notes” and such offering, the “Convertible Notes Offering”) and $200 million of its ...

November 10, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch